Position in NAMS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$414,493,576
+$58,893,398 QoQ
Shares Held
12,230,557
+10.1% QoQ
Ownership
10.2%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#2
of 198 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capital World Investors holds $27,435,334,973 across 33 Biotechnology names. NAMS ranks #11 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
26,115,014 | $12,972,110,904 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,144,846 | $3,354,932,991 | |
| 3 | ARGX |
Argenx SE
|
2,199,770 | $2,040,880,612 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
21,669,226 | $1,718,152,929 | |
| 5 | MRNA |
Moderna, Inc.
|
22,276,996 | $1,560,058,029 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
4,008,244 | $750,663,936 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
2,697,610 | $650,043,081 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
2,249,582 | $641,063,382 |
All Filings in NAMS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $414,493,576 | 12,230,557 | Shares | Defined | 2026-08-12 | |
| 2026-05-29 | $410,504,537 | 12,188,377 | Shares | Sole | 2026-06-04 | |
| 2026-03-31 | $355,600,178 | 11,109,034 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $350,238,720 | 9,984,000 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $279,357,900 | 9,822,711 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $151,901,699 | 8,387,725 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $139,167,301 | 6,798,598 | Shares | Defined | 2025-05-12 | |
| 2024-12-31 | $26,113,153 | 1,016,076 | Shares | Defined | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||